Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07117890) titled 'Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations' on Aug. 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Fudan University

Condition: Non Small Cell Lung Cancer

Intervention: Drug: Sunvozertinib

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: February 7, 2025

Target Sample Size: 14

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07117890

Published by HT Digital Content Servi...